Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sentinel Lymph Node Biopsy with Indocyanine Green in Rectal Cancer
NCT05830890Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of indocyanine green in rectal cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: False negative rate of sentinel lymph node biopsy up to 14 days and Accuracy of sentinel lymph node biopsy up to 14 days. Planned start May 2023; status: not yet recruiting.
02
Drugs
indocyanine green
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05830890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05830890.